Background: Breast cancer is a leading type of cancer affecting women around the world. Its incidence is increasing in developed and developing countries. Breast cancer is the leading cause of death among women in Indonesia with 19,731 cases of death in 2014. In addition to mortality, breast cancer causes psychosocial effect in the affected and the family. This study aimed to determine the risk factors of breast cancer in women at Dr. Moewardi Hospital, Surakarta, Central Java.
In developed countries, the number of deaths from breast cancer amounted to 197,600 deaths. This breast cancer specific death rate was lower than that in the developing countries. For example, in the United States by 2015 there were 231,840 new cases and 40,290 deaths due to breast cancer (Di Sibio et al., 2016) .
In Southeast Asia, the incidence rate of breast cancer was 27% of all cancers in women. Breast cancer mortality rate was 18% of all deaths from breast cancer (Graham et al., 2016) .
In Indonesia, the incidence of breast cancer was 48,998 cases with 19,731 deaths (Ministry of Health RI Center for Data and Health Information, 2015) . In 2013, the highest prevalence of breast cancer occurred in Yogyakarta Province, which was 4.1%. This figure was higher than the national rate of 1.4%. The highest prevalence of breast cancer occurred in Central Java and Bali, ie 2.1% and 2.0% (Ministry of Health RI Center for Data and Information Health, 2016) .
To the extent of the author's knowledge, studies on the risk factors of breast cancer using multiple regression analysis in Indonesia are sparse. Based on the background, the author were interested to examine the risk factors of breast cancer in women at Dr. Moewardi Hospital, Surakarta.
SUBJECTS AND METHOD 1. Study design
This was an analytic observational study with a case control design. The study was conducted at Mawar III ward, Dr. Moewardi Hospital, Surakarta, Central Java, Indonesia, from October to December 2017.
Population and sample
A sample of 200 study subjects was selected for this study by fixed disease sampling, consisting of 100 breast cancer patients and 100 non breast cancer in-patients in Mawar ward, Dr. Moewardi hospital, Surakarta with 1:1 ratio.
The exclusion criteria were inpatients who had complication disease or had psychiatric disorder, unable to read or write.
Study variables
The dependent variable was breast cancer. The independent variables were age at menarche, age at first pregnancy, parity, duration of breastfeeding, use of fertility hormone, duration of hormonal contraceptive use, and age at menopause.
Operational definition of variables
Breast cancer was defined as an abnormal growth of abnormal breast tissue with excessive growth, no coordination with normal tissue growth, grows infiltratively and destructively, and may metastasize and will continue to grow. The data of breast cancer cases and non breast cancer control were taken from the medical record. The measurement scale was categorical, coded 0 for non breast cancer and 1 for breast cancer.
Age at menarche was defined as the maternal age (year) at the first menstrual cycle. The data were collected by questionnaire. The measurement scale was continuous, but for the purpose of analysis transform into dichotomous, coded 0 for ≥12 years old and 1 for <12 years old.
Age at first pregnancy was defined as maternal age (year) at the first pregnancy. The data were collected by questionnaire. The measurement scale was continuous, but for the purpose of analysis transform into dichotomous, coded 0 for <30 years old and 1 for ≥30 years old.
Parity was defined as the number of children who had been born. The data were collected by questionnaire. The measurement scale was continuous.
Birth spacing was defined as the time interval (year) from previous child birth until the current pregnancy. The data were collected by questionnaire. The measurement scale was continuous.
Length of contraceptive use was defined as the duration (year) of delaying or regulating the number of pregnancies using artificial hormones. The data were collected by questionnaire. The measurement scale was continuous, but for the purpose of analysis transform into dichotomous, coded 0 for <10 years and 1 for ≥10 years.
Data analysis
The sample characteristics were described in frequency, mean, standard deviation, minimum, and maximum, for continuous data. The sample characteristics were described in frequency and percent, for categorical data. The bivariate analysis involving categorical data was run by cross tabulation with odds ratio as the measure of the association and Chi square as the statistical test. The multivariate analysis employed a multiple logistic regression.
Research Ethics
The research ethical clearance was granted from the Research Ethics Committee at Dr. Moewardi Hospital, Surakarta, Central Java, Indonesia. Research ethics included issues such as informed consent, anonymity, confidentiality, and ethical clearance. Table 1 shows the descriptive characteristics of the sample consisting of 200 study subjects. Most of the study subjects aged 50-59 years (36.5%). As many as 62.0% study subjects attained <Senior high school. A few subjects were diploma or graduate (15.5%). One-third of the study subjects were housewives. Half of the study subjects had income <Rp 1,000,000. Table 2 shows the results of bivariate analysis between breast cancer and age at menarche, age at menopause, parity, and duration of contraceptive use. As expected the results of these crude analyses suggest associations between breast cancer and age at menarche, age at menopause, parity, and duration of contraceptive use. For example, women with age at menarche ≥12 years were 0.38 times less likely to have breast cancer than women with age at menarche <12 years. Similarly, women with hormonal contraceptive use ≥10 years were 3.60 times more likely to have breast cancer than women with <10 years. Table 3 shows the results of multiple logistic regression analysis on the risk factors of breast cancer in women. As expected, age at menarche was a moderate risk factor of breast cancer. Women with age at menarche <12 years were more likely to get breast cancer than age at menarche ≥12 years (OR= 2.71; 95% CI= 1.06 to 6.96; p= 0.037).
RESULTS

Univariate analysis
Bivariate analysis
Multivariate analysis
Age at first pregnancy was a strong risk factor of breast cancer. Women with age at first pregnancy ≥30 years were more likely to get breast cancer than age at menarche <30 years (OR= 3.01; 95% CI= 1.16 to 7.78; p= 0.023).
Age at menopause <55 years was a weak risk factor of breast cancer. Women with age at menopause <55 years were more likely to get breast cancer than age at menopause ≥55 years (OR= 1.07; 95% CI= 0.82 to 6.30; p= 0.001).
Hormonal contraceptive use of ≥10 years was a strong risk factor of breast cancer. Women with hormonal contraceptive use ≥10 years were more likely to get breast cancer than women with hormonal contraceptive use <10 years (OR= 3.25; 95% CI= 1.20 to 9.63; p= 0.003).
DISCUSSION
From the multiple regression analysis of the present study, it was indicated that all of the dependent variables investigated in this study i.e. age at menarche, age at menopause, age at first pregnancy, and use of hormonal contraceptive, were associated with the risk of breast cancer. 1. The association between age at menarche and breast cancer Menarche marks the onset of ovarian activity associated with reproduction, and affect breast cancer risk. During women's reproductive years (broadly the time between menarche and menopause) the ovary produces steroid hormones that directly affect development and function of the breast. Early menarche and late menopause are known to increase women's risk of developing breast cancer (Collaborative Group on Hormonal Factors in Breast Cancer, 2012).
The present study found that age at menarche had a significant relationship with breast cancer in women. The result of the multivariate analysis shows that age at menarche <12 years increased the risk of breast cancer (OR = 2.71; 95% CI = 1.06 to 6.96; p = 0.037).
This result is consistent with Li et al., (2017) which stated that age at menarche had a significant relationship with the incidence of breast cancer.
This study is also consistent with a meta-analysis, which reported that breast cancer risk increased by a factor of 1.05 (95% CI= 1.04-1.06; p<0.001) for every year younger at menarche (Collaborative Group on Hormonal Factors in Breast Cancer, 2012).
Too early menarche, which is less than 12 years, causes early exposure to estrogen hormone. In turn, the increased estrogen hormone causes the abnormal growth of cells. Breast cancer can occur due to estrogen stimulation of epithelial cell division. Estrogen with its metabolites directly acts as a mutagen, which results in the emergence of cancer cells (Hamajima et al., 2012) .
Conversely, the estrogen hormone prevents heart attack and protects bones. Insufficient estrogen hormone at a young age increases a woman's risk for heart or bone disorders (Ewaid and Al-Azzawi, 2016 ).
This result is consistent with Ewaid and Al-Azzawi studies (2016) which reported that early menstrual period <12 years were associated with an increased risk of breast cancer. Conversely, age menarche ≥17 years were associated with a decreased risk of breast cancer by 30%.
The association between age at first pregnancy and the risk of breast cancer
This study found that age at first pregnancy was a strong risk factor of breast cancer. Women with age at first pregnancy ≥30 years were more likely to get breast cancer than age at menarche <30 years.
The fact that reproductive factors have significant influence on the risk of breast cancer is well known. Early age of first full-term birth is highly protective against late-onset breast cancers, but each pregnancy, including the first one, increases the risk of early-onset breast cancer (Kobayashi et al., 2012) . This is possible because at the firsttrimester pregnancy the estrogen hormone level is high, resulting in the process of cell multiplication through rapid mitosis that causes cancer cell division (Becker, 2015; Goldberg et al., 2015; Morales et al., 2013) .
This study is consistent with the study of Mockus et al. (2015) which states that the increased risk for breast cancer is associated with increased age at first pregnancy.
Delay of first birth together with low parity and short duration of breast feeding are increasing social trends in developed countries. Therefore, breast cancer risk as a result of reproductive factors will not decrease in these countries in the foreseeable future (Kobayashi et al., 2012) .
The association between age at menopause and the risk of breast cancer
Menopause marks the cessation of ovarian activity associated with reproduction, and affect breast cancer risk (Collaborative Group on Hormonal Factors in Breast Cancer, 2012) .
The present study found that age at menopause <55 years was a weak risk factor of breast cancer. Women with age at menopause <55 years were more likely to get breast cancer than age at menopause ≥55 years.
Women who experience menopause at older ages have longer exposure of estrogen hormone in the blood, which will result in an increased risk of breast cancer (Bakht and Najafi, 2010; Mahmoud et al., 2015; Nagrani et al., 2016) .
The period between first menstrual occurrence and age at first pregnancy is a window of initiation of breast cancer development. Anatomically and functionally, the breasts will experience atrophy according to age. Less than 25% of breast cancers occur prior to menopause (Becker, 2015 , Morales et al., 2013 . Women with menopause at age 55 or older have a 50% higher risk of breast cancer than less than 55 years. Similarly, women with menopause less than 45 years have a 30% higher risk of breast cancer than over 45 years (Mockus et al., 2015) .
The main risk of breast cancer is the increasing age of the individual. The longer a person lives, the higher the risk of cancer because of the physical condition decreases and easily becomes abnormal (Laamiri et al., 2015; Mahmoud et al., 2015; Nagrani et al., 2016) .
As discussed above, prior studies indicate that women with menopausal symptoms have lower estrogen levels because they go through menopause as compared with women who do not experience them. Given the central role of hormones in the etiology of breast cancer, a link between menopausal symptoms and breast cancer is plausible. Huang et al. (2011) went further to evaluate the association between menopausal symptoms and breast cancer risk. The authors found that women who ever experienced menopausal symptoms had lower risks of invasive ductal carcinoma (IDC) (OR = 0.5; 95% CI: 0.3-0.7), invasive lobular carcinoma (ILC) (OR = 0.5; 95% CI: 0.3-0.8), and invasive ductal-lobular carcinoma (IDLC) (OR = 0.7; 95% CI: 0.4-1.2). These reductions in risk were independent of recency and timing of hormone therapy use, age at menopause, and body mass index. Increasing intensity of hot flushes among women who ever experienced hot flushes was also associated with decreasing risks of all three breast cancer subtypes (P values for trend all ≤ 0.017). Huang et al. (2011) concludes that women who ever experienced menopausal symptoms have a substantially reduced risk of breast cancer, and that severity of hot flushes is also inversely associated with risk.
The association between use of contraceptive and the risk of breast cancer
This study found that the longer using hormonal contraceptives will provide increased risk of breast cancer. Women who use hormonal contraceptives <10 years are at lower risk than women who never use hormonal contraceptives.
The result of the present study is consistent with a prospective cohort study by Kumle et al. (2002) , which was specifically designed to examine the role of hormonal contraceptives in relation to breast cancer was conducted in Norway and Sweden. This study was entitled Women's Lifestyle and Health. Of 196,000 invited women aged 30-49 years, 106,844 women answered a 4-page questionnaire. Altogether, 103,027 women providing information on contraceptive use were included in the analysis, and 1,008 primary invasive breast cancers were diagnosed throughout 1999 (end of follow-up). The author used proportional hazard regression model to calculate relative risks (RRs) with adjustment for age and other possible confounders. An increased breast cancer risk was observed among women who were recent users of oral contraceptives (OCs) of any type at the start of follow-up (RR= 1.6; 95% CI= 1.2-2.1).
The loss of the cellular function of the programmed cell (apoptosis) will lead to the inability to detect the presence or absence of cell damage resulting from damage to DNA, so that abnormal cells will continue to be uncontrollably polymerized (Mahmoud et al., 2015; Nakamura et al. , 2017) .
The result of this study is consistent with the study conducted by Youlden et al. (2014) , which stated that there was a significant relationship between the hormonal contraceptives use and the risk of breast cancer.
Devi (2011) stated that women who consumed combined contraceptive pill had a risk of 1.86 times for breast cancer than those with the non-combined contraceptive method. The duration of combined contraceptive method use in the case group was highest in the 5-9 year of age group (Oktaviana, 2011) . Li et al. (2017b) conducted a metaanalysis to investigate the association between oral contraceptive use as a risk factor and triple-negative breast cancer. The study indicated that women who used OCs had a greater risk of TNBC compared with women who did not. This conclusion prompts that women who used OCs should be examined more closely in population screenings of breast cancer, as they may benefit from prevention and early detection strategies.
The association between oral contraceptive use and risk of breast cancer was also evident by histologic type of the breast cancer. Newcomer et al. (2003) examined the association between oral contraceptive use and risk of specific breast cancer histopathologies in a large, multicenter, population-based, case-control study. Women younger than age 75 with a new diagnosis of invasive breast cancer were identified from 4 statewide tumor registries. The authors compared women with lobular (n= 493) and ductal carcinoma (n= 5,510) to randomly selected controls (n= 9,311). Odds ratios (OR) and 95% confidence intervals (CI) for each histologic type were estimated using polytomous logistic regression, adjusted for other breast cancer risk factors. Current oral contraceptive use was associated with increased risk of lobular carcinoma (OR= 2.6, 95% CI= 1.0 to 7.1) and there was a significant trend (p= 0.017) of increased risk with more recent use. Oral contraceptive use was not clearly associated with ductal carcinoma (OR= 1.2, 95% CI= 0.8 to 1.9). These results suggest that the association between oral contraceptive use and risk of breast cancer may vary by histologic type.
The present study concludes that the risk of breast cancer increases with earlier age at menarche, delayed age at first pregnancy, delayed age at menopause, and longer hormonal contraceptive use.
